All In Biotech

Drug Trial Radar · NCT07102511

Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH

Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, With Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy (LIBerate-Kids)

Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. Randomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

150

Planned (sponsor's estimate)

Start

Jul 20, 2026

Primary completion

Jul 31, 2028

Study completion Nov 30, 2028

Sponsor

Lead sponsor
LIB Therapeutics LLCIndustry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Aug 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the LDL-Cholesterol reductions at Week 12 and Week 24 with monthly dosing of lerodalcibep (Lerochol) 300 mg administered subcutaneously by auto-injector (AI)/pre-filled pen (PFP) compared to placebo (dummy), in male and female pediatric patients 6 to 17 years of age, with inherited high cholesterol (HeFH) on a stable diet and maximally tolerated oral LDL C lowering drug therapy such as statins. The main question\[s\] it aims to answer are: How effective is Lerochol in reducing LDL cholesterol? How well is it tolerated and are there any safety concerns? Researchers will compare Lerochol to placebo (inert or dummy injection solution). Participants will visit the clinic every month for months and be asked to fast overnight, but allowed to drink water, before clinic visits. Undergo physical exams, height and weight measurements, answer questions, have blood drawn from a vein in their arm, have blood pressure measurements, EKC heart tests, and receive monthly injections lasting about 5 seconds in their arms or abdomen with an autoinjector.

Conditions

  • Familial Hypercholesterolemia - Heterozygous

Interventions

  • lerodalcibep 300 mg Monthly SCBiological

    lerodalcibep or placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Low Density Lipoprotein cholesterol at week 12Time frame: Week 12

Locations

7 sites in 6 countries. Site status is shown where the registry gives one.

  • Metabolic & Atherosclerosis Research Center

    Cincinnati, Ohio

  • Lipid Clinic Hadassah Medical Center

    Jerusalem, Israel

  • New Zealand Clinical Research

    Christchurch, New Zealand

  • The Lipid Clinic Oslo University Hospital

    Oslo, Norway

  • Iatros International

    Bloemfontein, Free State, South Africa

  • Lipid Clinic Wits University

    Johannesburg, Gauteng, South Africa

  • Ege Universitesi Tip Fakultesi

    Izmir, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.